Download the full white paper for a comprehensive look at the implications of the proposed EU Pharma Package and key considerations from experts that may help organizations prepare for what comes next.

The proposed EU Pharma Package represents one of the most significant regulatory updates Europe has considered in years. While discussions have largely focused on market exclusivity reforms, the broader implications extend much further. Potential changes could influence launch sequencing, development planning, supply obligations, and how organizations approach long-term commercialization strategies across European markets.

For biopharma manufacturers and regulatory leaders, these proposals introduce new considerations that may require closer coordination across regulatory, clinical, and operational teams. Development decisions that were once broadly global in nature may increasingly require earlier market-specific planning, particularly as organizations evaluate how evolving incentives and requirements could affect product strategy.

The challenge is not simply understanding what is changing. It is understanding how those changes may influence decisions already being made today.

To help organizations navigate these evolving considerations, Project Farma developed Navigating the EU Pharma Package, designed to help regulatory and industry leaders better understand the proposed changes and evaluate potential impacts on development planning, launch strategy, and long-term decision making.